Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505918 | 0.92 | SLC6A4 (0.85) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| Vanoxerine SCHEMBL246574 | 0.87 | SLC6A4 (1.00) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| SCHEMBL10000765 | 0.86 | SLC6A4 (0.97) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| Vanoxerine SCHEMBL725103 | 0.86 | SLC6A4 (1.00) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| Vanoxerine SCHEMBL15541249 | 0.86 | SLC6A4 (1.00) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| Vanoxerine SCHEMBL3014060 | 0.85 | SLC6A4 (0.95) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| SCHEMBL7325179 | 0.83 | SLC6A4 (0.71) | SLC6A3SLC6A4CYP2D6KCNH2SIGMAR1 | |
| SCHEMBL6254945 | 0.82 | SLC6A4 (0.90) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| SCHEMBL24221220 | 0.82 | SLC6A4 (0.88) | SLC6A3SLC6A4CYP2D6SLC6A2MEN1 | |
| Hydrochloric Acid SCHEMBL7319263 | 0.82 | SLC6A4 (0.69) | SLC6A3SLC6A4CYP2D6KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | ADERANS RESEARCH INSTITUTE, INC. | 2012-09-27 | — | — | US | disclosed |
| US-8273747-B2 | tert-Butyl (4-((4'-cyano-4-methoxy-biphenyl-3-ylmethyl)-amino)-cyclohexyl)-methyl-carbamate; hedgehog pathway agonists; alopecia; angiogenesis; wound healing; alzheimer's disease; inhibit aging effects on skin | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8211916-B2 | Central nervous system disorders; drug abuse; Parkinson's disease; antidepressants | WAYNE STATE UNIVERSITY (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2291378-A2 | N- AND O-SUBSTITUTED 4-Ý2-(DIPHENYLMETHOXY)-ETHYL¨-1-Ý(PHENYL)METHYL¨PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | WAYNE STATE UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595331-B2 | N-and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith | WAYNE STATE UNIVERSITY (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009094428-A2 | N- AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | CURIS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20020161002-A1 | Norepinephrine reuptake inhibitors; to increase memory function such as long-term memory and recall ability | SENTION, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020115725-A1 | Methods and compositions for regulating memory consolidation | PRIESTLEY, KATHERINE (GB) | 2002-08-22 | — | — | US | disclosed |
| US-20020103162-A1 | Use of threo-methylphenidate compounds to enhance memory | SENTION, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002053104-A2 | USE OF CATECHOLAMINE REUPTAKE INHIBITORS TO ENHANCE MEMORY | SENTION, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002039998-A2 | METHODS AND COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION | SENTION, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002017920-A2 | USE OF METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY | SENTION, INC (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002017919-A2 | USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY | SENTION, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001098266-A2 | N-AND O-SUBSTITUTED 4-[2-(DIPHENYLMETHOXY)-ETHYL]-1-[(PHENYL)METHYL]PIPERIDINE ANALOGS AND METHODS OF TREATING CNS DISORDERS THEREWITH | WAYNE STATE UNIVERSITY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6218595-B1 | GENETICALLY ENGINEERED CELLS; FOR USE AS TEST MODELS IN THE TREATMENT OF PARKINSON'S DISEASE OR DYSKINESIS | DUKE UNIVERSITY | 2001-04-17 | — | — | US | disclosed |
| WO-1997012513-A1 | DOPAMINE TRANSPORTER KNOCKOUT MICE | DUKE UNIVERSITY (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016600-A1 | N- and O-Substituted 4-[2-(Diphenylmethoxy)-Ethyl]-1-[(Phenyl)Methyl]Piperdine Analogs and Methods of Treating CNS Disorders Therewith | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CYP2D6 322/4885 |
| US-20080193423-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | SLC6A3 4302/4885SLC6A4 4446/4885CYP2D6 4780/4885 |
| US-20120245184-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | GLI1, SHH, SMO | SLC6A3 4302/4885SLC6A4 4446/4885CYP2D6 4780/4885 |
| US-20020103162-A1 | Use of threo-methylphenidate compounds to enhance memory | SLC6A3, SLC6A2, PNMT | SLC6A3 1/4885SLC6A4 4/4885CYP2D6 1069/4885 |
| US-20080194637-A1 | Small organic molecule regulators of cell proliferation | GLI1, SHH, SMO | SLC6A3 4302/4885SLC6A4 4446/4885CYP2D6 4780/4885 |
| US-20020115725-A1 | Methods and compositions for regulating memory consolidation | BDNF, CHAT, GAP43 | SLC6A3 1970/4885SLC6A4 2396/4885CYP2D6 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.